| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Scopolin is a novel and potent glucoside. Which is a a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots and attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades.
| ln Vitro |
In HepG2 cells, scopin (100 μM, 24 hours) prevents base buildup brought on by oleic acid by raising SIRT1 activity [2]. The pre-osteoclast RAW 264.7 cells' ability to secrete osteoclasts generated by RANKL is inhibited by Scopolin (10 μM, 5 days) [5].
|
|---|---|
| ln Vivo |
In HFD-fed infants, scopicon (0.02% (w/w) in the diet for 8 weeks) decreases myocardial steatosis and reduces weight gain [2]. Extracellular choline in stored brain increases to about 300% when scopolin (2 μmol, icv) is added [3]. By inhibiting both angiogenesis and adjuvant, scopolamine (50, 100 mg/kg, intraperitoneal injection) prevents adjuvant-induced arthritis [4].
|
| Animal Protocol |
Animal/Disease Models: HFD-fed C57BL/6 N mice [2]
Doses: 0.02% (w/w) HFD in diet (equivalent to 20 mg/kg body weight) Route of Administration: Supplementation in diet, 8 weeks Experimental Results: Reversal HFD-induced hepatic TG, cholesterol, and fatty acid accumulation increased by 35%, 49%, and 35%, respectively. Reversed the HFD-induced decrease in plasma adiponectin levels by 76% and diminished elevated plasma MCP-1, TNFα, and IL-6 levels. The HFD-induced downregulation of SIRT1 activity was restored. Animal/Disease Models: Adjuvant-induced arthritis (AIA) rats [4] Doses: 50, 100 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Inhibition of swelling and joint index scores in vaccinated and unvaccinated paws. Reduce new blood vessels and reduce the expression of IL-6, VEGF and FGF-2 in rat synovial tissue. |
| References |
|
| Additional Infomation |
Scopolin is a member of the class of coumarins that is scopoletin attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It has a role as a plant metabolite. It is a monosaccharide derivative, a member of coumarins and a beta-D-glucoside. It is functionally related to a scopoletin.
Scopolin has been reported in Erycibe obtusifolia, Mandragora autumnalis, and other organisms with data available. See also: Chamaemelum nobile flower (part of). |
| Molecular Formula |
C16H18O9
|
|---|---|
| Molecular Weight |
354.31
|
| Exact Mass |
354.095
|
| CAS # |
531-44-2
|
| PubChem CID |
439514
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
650.2±55.0 °C at 760 mmHg
|
| Melting Point |
217ºC
|
| Flash Point |
241.5±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
-1.87
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
510
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1C([H])=C2C(C([H])=C([H])C(=O)O2)=C([H])C=1OC([H])([H])[H]
|
| InChi Key |
SGTCGCCQZOUMJJ-YMILTQATSA-N
|
| InChi Code |
InChI=1S/C16H18O9/c1-22-9-4-7-2-3-12(18)23-8(7)5-10(9)24-16-15(21)14(20)13(19)11(6-17)25-16/h2-5,11,13-17,19-21H,6H2,1H3/t11-,13-,14+,15-,16-/m1/s1
|
| Chemical Name |
6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
|
| Synonyms |
Scopolin ScopolosideMurrayin NSC404560 NSC-404560NSC 404560
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8224 mL | 14.1119 mL | 28.2239 mL | |
| 5 mM | 0.5645 mL | 2.8224 mL | 5.6448 mL | |
| 10 mM | 0.2822 mL | 1.4112 mL | 2.8224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
